Datwyler increased its revenue from continuing operations by 21.4% to CHF 1'150.6 million in 2022. Adjusted for currency effects and acquisitions, this equates to organic growth of 10.4%. With an operating result (EBIT) of CHF 149.2 million, Datwyler’s EBIT margin was 13.0%, achieving the objective communicated in May. The Annual General Meeting will be asked to approve a cash dividend of CHF 3.20 per bearer share, which corresponds to a payout ratio of 51.9%. Through the acquisitions of QSR and Xinhui, the second healthcare plant in India and progress with growth and innovation projects, Datwyler has further strengthened its strategic position. For 2023, Datwyler is aiming to improve its business result.

In the first half of 2022 Datwyler increased revenue from continuing operations by 11.7% to CHF 541.6 million in a difficult environment. The sharp rise in input costs, negative effects of acquisitions and delayed impact of successfully implemented price increases caused the operating result (EBIT) to decline to CHF 72.5 million and the EBIT margin to 13.4%. With the strategic acquisitions of QSR and Xinhui, Datwyler further strengthened the basis for future profitable growth in attractive markets.

Datwyler, a leading manufacturer of elastomer components for pharmaceutical packaging, is expanding its portfolio with two new products to meet evolving patient demands. The new offerings include a 5/8 in. rigid needle shield (RNS) to address the rising need for prefilled syringes to contain vaccines for intramuscular injection, and isoprene rubber discs for infusion therapies.

The geopolitical developments of recent months have caused Datwyler's input costs to rise sharply at all locations. At the same time, the ongoing shortage of electronic components in the automotive industry and the pandemic lockdowns in China have dampened revenue growth despite Datwyler's unrestricted delivery capability. Due to the delayed effect of the implemented price increases and cost savings, there is a temporary pressure on margins.

Datwyler closed the acquisition of Yantai Xinhui Packing announced on December 7, 2021, on March 1, 2022, thus becoming the owner of the Chinese company. This strategically important acquisition gives Datwyler direct access to the fast-growing healthcare market in China.